XML 31 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
CAPITAL STOCK
12 Months Ended
Dec. 31, 2017
CAPITAL STOCK

NOTE H — CAPITAL STOCK

Cash dividends

Dividends were declared in 2017 and 2016 as follows:

 

Dividend per share

   Date declared    Date of record    Payment date

$0.0425

   March 3, 2016    May 2, 2016    May 16, 2016

$0.0425

   June 9, 2016    August 1, 2016    August 15, 2016

$0.0425

   August 4, 2016    November 1, 2016    November 15, 2016

$0.0425

   November 3, 2016    February 1, 2017    February 15, 2017

$0.0425

   March 8, 2017    May 1, 2017    May 15, 2017

$0.0425

   June 22, 2017    August 1, 2017    August 15, 2017

$0.0425

   August 4, 2017    November 1, 2017    November 15, 2017

$0.0425

   November 7, 2017    February 1, 2018    February 15, 2018

On March 8, 2018, the Board of Directors declared a quarterly dividend of $0.0425 per share payable on May 15, 2018 to shareholders of record on May 1, 2018.

Stock repurchase program

On April 30, 2013, Lifetime’s Board of Directors authorized the repurchase of up to $10.0 million of the Company’s common stock. The repurchase authorization permits the Company to effect repurchases from time to time through open market purchases and privately negotiated transactions. No shares were repurchased during the years ended December 31, 2017, 2016 and 2015.

Preferred stock

The Company is authorized to issue 100 shares of Series A Preferred Stock and 2,000,000 shares of Series B Preferred Stock, none of which has been issued or is outstanding at December 31, 2017.

Long-term incentive plan

The Company’s Amended and Restated 2000 Long-Term Incentive Plan (the “Plan”) provides for the granting of awards of up to 5,287,500 shares of common stock. These shares of the Company’s common stock are available for grants to directors, officers, employees, consultants and service providers and affiliates in the form of stock options or other equity-based awards. The Plan authorizes the Board of Directors of the Company, or a duly appointed committee thereof, to issue incentive stock options, non-qualified options, restricted stock, performance based awards and other stock-based awards. Options that have been granted under the Plan expire over a range of five to ten years from the date of grant and vest over a range of up to four years from the date of grant. Shares of restricted stock that have been granted under the Plan vest over a range of up to four years from the date of grant. Performance based awards that have been granted under the Plan vest after three years based upon the attainment of specified performance goals. In June 2017, the shareholders of the Company approved an amendment to the Company’s Plan to revise the terms and conditions of Plan to increase the shares available for grant under the plan by 437,500 shares and include and clarify several features that promote good governance. As of December 31, 2017, there were 619,369 shares available for the grant of awards.

 

Stock options

A summary of the Company’s stock option activity and related information for the three years ended December 31, 2017, is as follows:

 

     Options      Weighted-
average
exercise
price
     Weighted-
average
remaining
contractual
life (years)
     Aggregate
intrinsic
value
 

Options outstanding at December 31, 2014

     2,326,627      $ 14.19        

Grants

     89,600        13.99        

Exercises

     (110,375      8.84        

Cancellations

     (37,750      15.57        

Expirations

     (25,900      26.60        
  

 

 

          

Options outstanding at December 31, 2015

     2,242,202        14.28        

Grants

     66,850        15.44        

Exercises

     (272,325      9.01        

Cancellations

     (30,750      15.39        

Expirations

     (230,577      27.16        
  

 

 

          

Options outstanding at December 31, 2016

     1,775,400        13.44        

Grants

     125,750        17.38        

Exercises

     (300,000      11.34        

Cancellations

     (45,700      16.40        

Expirations

     (99,250      20.40        
  

 

 

          

Options outstanding at December 31, 2017

     1,456,200        13.64        4.6      $ 5,019,000  
  

 

 

          

 

 

 

Options exercisable at December 31, 2017

     1,250,673      $ 13.05        4.0      $ 4,923,000  
  

 

 

          

 

 

 

The aggregate intrinsic value in the table above represents the total pre-tax intrinsic value that would have been received by the option holders had all option holders exercised their in-the-money stock options on December 31, 2017. The intrinsic value is calculated for each in-the-money stock option as the difference between the closing price of the Company’s common stock on December 31, 2017 and the exercise price.

The total intrinsic values of those stock options that were exercised in the years ended December 31, 2017, 2016 and 2015 were $2,071,000, $1,848,000 and $639,000, respectively. The intrinsic value of a stock option that is exercised is calculated at the date of exercise.

Total unrecognized stock option compensation expense at December 31, 2017, before the effect of income taxes, was $1.0 million and is expected to be recognized over a weighted-average period of 2.1 years.

The Company values stock options using the Black-Scholes option valuation model. The Black-Scholes option valuation model, as well as other available models, was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. The Black-Scholes option valuation model requires the input of highly subjective assumptions including the expected stock price volatility and risk-free interest rate. Because the Company’s stock options have characteristics significantly different from those of traded options, changes in the subjective input assumptions can materially affect the fair value estimates of the Company’s stock options. The weighted-average per share grant date fair value of stock options granted during the years ended December 31, 2017, 2016, and 2015 was $6.37, $5.43 and $4.68, respectively.

The fair values for these stock options were estimated at the dates of grant using the following weighted-average assumptions:

 

     2017     2016     2015  

Historical volatility

     39     39     39

Expected term (years)

     6.0       6.0       5.2  

Risk-free interest rate

     1.97     1.37     1.67

Expected dividend yield

     0.98     1.10     1.18

 

Restricted Stock

A summary of the Company’s restricted stock activity and related information for the three years ended December 31, 2017 is as follows:

 

     Restricted
Shares
     Weighted-
average
grant date
fair value
 

Non-vested restricted shares, December 31, 2014

     26,511      $ 15.86  

Grants

     100,073        14.78  

Vested

     (24,649      15.97  

Cancellations

     (500      14.84  
  

 

 

    

Non-vested restricted shares, December 31, 2015

     101,435        14.77  

Grants

     109,170        15.64  

Vested

     (46,306      14.79  

Cancellations

     (2,475      14.93  
  

 

 

    

Non-vested restricted shares, December 31, 2016

     161,824        15.35  

Grants

     133,352        18.32  

Vested

     (69,795      15.39  

Cancellations

     (6,064      16.07  
  

 

 

    

Non-vested restricted shares, December 31, 2017

     219,317      $ 17.12  
  

 

 

    

Total unrecognized compensation expense remaining

   $ 2,932,000     

Weighted-average years expected to be recognized over

     2.6     

The total fair value of restricted stock that vested during the year ended December 31, 2017 was $1.3 million.

Performance shares

Each performance award represents the right to receive up to 150% of the target number of shares of common stock. The number of shares of common stock earned will be determined based on the attainment of specified performance goals at the end of the performance period, as determined by the Compensation Committee of the Board of Directors. The shares are subject to the terms and conditions of the Plan.

 

A summary of the Company’s performance-based award activity and related information for the three years ended December 31, 2017 is as follows:

 

     Performance-
based

awards (1)
     Weighted-
average
grant date
fair value
 

Non-vested performance-based awards, January 1, 2015

     —        $ —    

Grants

     66,650        14.84  

Cancellations

     (500      14.84  
  

 

 

    

Non-vested performance-based awards, December 31, 2015

     66,150        14.84  

Grants

     82,000        15.69  

Cancellations

     (2,188      14.94  
  

 

 

    

Non-vested performance-based awards, December 31, 2016

     145,962        15.32  

Grants

     87,000        18.45  

Cancellations

     (4,070      16.52  
  

 

 

    

Non-vested performance-based awards, December 31, 2017

     228,892      $ 16.49  
  

 

 

    

Total unrecognized compensation expense remaining

   $ 1,727,000     

Weighted-average years expected to be recognized over

     1.7     

 

(1) Represents the target number of shares to be issued for each performance-based award.

On March 7, 2018, the Compensation Committee of the Board of Directors determined the performance goals set forth in the performance-based awards granted in 2015 were attained and 58,888 shares vested.

The Company recognized total stock compensation expense of $3.4 million for the year ended December 31, 2017, of which $1.1 million represents stock option compensation expense and $2.3 million represents restricted stock and performance based compensation expense. The Company recognized total stock compensation expense of $2.9 million for the year ended December 31, 2016, of which $1.4 million represents stock option compensation expense, $1.5 million represents restricted stock, including restricted stock granted to directors and performance based compensation expense, and $32,000 represents stock awards. The Company recognized total stock compensation expense of $5.3 million for the year ended December 31, 2015, of which $2.2 million represents stock option compensation expense, $0.8 million represents restricted stock including restricted stock granted to directors and performance based compensation expense, and $2.2 million represents stock awards.